A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer

A first-in-human study using BDC-4182 as a single agent in gastric and gastroesophageal cancers

Trial Details

NCT ID
NCT06921837
Phase
PHASE1 / PHASE2
Sponsor
Bolt Biotherapeutics, Inc.
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • BDC-4182
Locations (sample)
  • Darlinghurst, New South Wales, Australia|-33.87939,151.21925
  • Westmead, New South Wales, Australia|-33.80383,150.98768
  • Birtinya, Queensland, Australia|-26.74322,153.11913
  • Clayton, Victoria, Australia|-37.91667,145.11667
  • Heidelberg, Victoria, Australia|-37.75,145.06667

Key Eligibility Criteria

  • Has disease that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1.
  • Subjects must have histologically/cytologically confirmed gastric or gastroesophageal cancer that is metastatic (Stage 4) or unresectable (Stage 3).
  • Subjects must have received at least 1-2 prior lines of locally available standard therapies or must be intolerant of standard therapies.
  • For subjects in escalation: If prior Claudin 18 IHC expression is known, the subject must have some degree of Claudin 18 expression as defined as P…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →